Table 2.
Univariate and multivariate Cox-regression analysis for survival using known prognostic factors in hormone refractory prostate cancer, prostate-specific antigen and prostate-specific antigen half-life
| Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| Variable | No. | Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | p value |
| Gleason at initial diagnosis | |||||
| ≤6 | 68 | 1.0 | – | 1.0 | – |
| 7 | 23 | 1.20 (0.62–2.33) | 0.58 | 3.85 (0.71–20.77) | 0.12 |
| 8–10 | 63 | 0.99 (0.62–1.58) | 0.96 | 0.77 (0.20–2.75) | 0.68 |
| PSA at initial diagnosis | |||||
| <20 | 40 | 1.0 | – | 1.0 | – |
| ≥20 | 75 | 0.79 (0.48–1.30) | 0.35 | 1.02 (0.33–3.10) | 0.97 |
| Stage at initial diagnosis | |||||
| Tx | 69 | 1.0 | – | 1.0 | – |
| N1-2 or M1 (5–7) | 71 | 0.71 (0.45–1.11) | 0.13 | 0.41 (0.10–1.62) | 0.21 |
| Age at start of docetaxel | |||||
| <70 | 70 | 1.0 | – | 1.0 | – |
| ≥70 | 84 | 1.29 (0.83–2.00) | 0.26 | 0.35 (0.09–1.27) | 0.11 |
| Hb at start of docetaxel | |||||
| Normal | 105 | 1.0 | – | 1.0 | – |
| Low (<120) | 47 | 2.61 (1.67–4.10) | <0.0001 | 0.67 (0.20–2.31) | 0.53 |
| Alk phos at start of docetaxel | |||||
| Normal | 69 | 1.0 | – | 1.0 | – |
| High (>150) | 78 | 2.59 (1.60–4.20) | 0.0001 | 2.43 (0.79–7.47) | 0.12 |
| LDH at start of docetaxel | |||||
| Normal | 54 | 1.0 | – | 1.0 | – |
| High (>350) | 89 | 1.18 (0.74–1.88) | 0.49 | 1.92 (0.57–6.46) | 0.29 |
| Early pre-chemotherapy PSADT | |||||
| >70 days | 55 | 1.0 | – | 1.0 | – |
| ≤70 days | 93 | 0.69 (0.44–1.09) | 0.12 | 0.76 (0.29–1.98) | 0.58 |
| PSA response 84 days after docetaxel | |||||
| <50% decline | 70 | 1.0 | – | 1.0 | – |
| ≥50% decline | 55 | 0.38 (0.22–0.67) | 0.0007 | 0.16 (0.05–0.48) | 0.001 |
| PSAHL 42 days after docetaxel | |||||
| >71 days | 56 | 1.0 | – | 1.0 | – |
| ≤71 days | 33 | 0.66 (0.36–1.23) | 0.2 | 0.86 (0.23–1.67) | 0.34 |
| PSAHL 84 days after docetaxel | |||||
| >70 days | 47 | 1.0 | – | 1.0 | – |
| ≤70 days | 45 | 0.34 (0.18–0.64) | 0.009 | 0.08 (0.021–0.34) | 0.0005 |
CI = confidence interval; PSA = prostate-specific antigen; Tx = tumour; N0 = no regional lymph node metastasis; M0 = no distant metastasis; N1 = metastasis with a single lymph node mass 2 cm or less in greatest dimension, or multiple lymph nodes, 2 cm or less in greatest dimension; N2 = metastasis with a single lymph node mass larger than 2 cm, but no more than 5 cm in greatest dimension, or multiple lymph nodes, no more than 5 cm in greatest dimension; M1 = distant metastasis; LDH = lactate dehydrogenase; Hb = hemoglobin; Alk phos = alkaline phosphatase; PSADT = prostate-specific antigen doubling time; PSAHL = prostate-specific antigen half-life.